ECSP024388A - PROTEASE INHIBITORS - Google Patents
PROTEASE INHIBITORSInfo
- Publication number
- ECSP024388A ECSP024388A EC2002004388A ECSP024388A ECSP024388A EC SP024388 A ECSP024388 A EC SP024388A EC 2002004388 A EC2002004388 A EC 2002004388A EC SP024388 A ECSP024388 A EC SP024388A EC SP024388 A ECSP024388 A EC SP024388A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- provides
- proteases
- cathepsin
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epoxy Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un objetivo de la presente invención es proveer inhibidores de proteasa 4-amino-azepan-3-ona carbonil, particularmente los inhibidores de cisteína y serina proteasas, aún más particularmente los compuestos que inhiben las cisteína proteasas de la superfamilia de la papaína, todavía más particularmente los compuestos que inhiben las cisteina proteasas de la familia catepsina, más particularmente los compuestos que inhiben catepsina K y que son útiles para el tratamiento de enfermedades que pueden ser terapéuticamente modificadas por alteración de estas proteasas. De acuerdo con estos, en el primer aspecto, esta invención provee un compuesto según la Fórmula I, En otro aspecto, esta invención provee una composición farmacéutica formada de un compuesto de acuerdo a la Fórmula I y un transportador farmacéuticamente aceptable, diluyente o excipiente. Aún más, en otro aspecto esta invención provee intermediarios útiles en la preparación de los compuestos de la Fórmula I. En todavía otro aspecto, esta invención provee un método para tratar enfermedades en las que la patología de la enfermedad puede ser terapéuticamente modificada por inhibidores de proteasas de la superfamilia de la papaína, todavía más particularmente cisteína proteasas de la familia catepsina, y más particularmente catepsina K . En un sentido particular, los compuestos de esta invención son especialmente útiles para el tratamiento de enfermedades caracterizadas por pérdida ósea, tales como osteoporosis y enfermedades gingivales, tales como gingivitis y periodontitis, o por excesiva degradación del cartílago o la matriz , tales como osteoartritis y artritis reumatoidea.An objective of the present invention is to provide inhibitors of 4-amino-azepan-3-one carbonyl protease, particularly cysteine and serine protease inhibitors, even more particularly compounds that inhibit the cysteine proteases of the papain superfamily, still more particularly the compounds that inhibit the cysteine proteases of the cathepsin family, more particularly the compounds that inhibit cathepsin K and that are useful for the treatment of diseases that can be therapeutically modified by altering these proteases. According to these, in the first aspect, this invention provides a compound according to Formula I. In another aspect, this invention provides a pharmaceutical composition formed of a compound according to Formula I and a pharmaceutically acceptable carrier, diluent or excipient. Furthermore, in another aspect this invention provides useful intermediates in the preparation of the compounds of Formula I. In yet another aspect, this invention provides a method for treating diseases in which the disease pathology can be therapeutically modified by inhibitors of Papain superfamily proteases, even more particularly cysteine proteases of the cathepsin family, and more particularly cathepsin K. In a particular sense, the compounds of this invention are especially useful for the treatment of diseases characterized by bone loss, such as osteoporosis and gingival diseases, such as gingivitis and periodontitis, or by excessive degradation of the cartilage or matrix, such as osteoarthritis and Rheumatoid arthritis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59384500A | 2000-06-14 | 2000-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP024388A true ECSP024388A (en) | 2003-02-06 |
Family
ID=24376433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2002004388A ECSP024388A (en) | 2000-06-14 | 2002-12-12 | PROTEASE INHIBITORS |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1307204A4 (en) |
| JP (1) | JP2004503502A (en) |
| KR (1) | KR20030008220A (en) |
| CN (1) | CN1444481A (en) |
| AP (1) | AP2002002671A0 (en) |
| AR (1) | AR032622A1 (en) |
| AU (1) | AU2001268407A1 (en) |
| BG (1) | BG107327A (en) |
| BR (1) | BR0111693A (en) |
| CA (1) | CA2412353A1 (en) |
| CZ (1) | CZ20024086A3 (en) |
| EA (1) | EA200300018A1 (en) |
| EC (1) | ECSP024388A (en) |
| HU (1) | HUP0301231A2 (en) |
| IL (1) | IL153421A0 (en) |
| MA (1) | MA25758A1 (en) |
| MX (1) | MXPA02012442A (en) |
| NO (1) | NO20025786L (en) |
| NZ (1) | NZ522965A (en) |
| OA (1) | OA12288A (en) |
| PE (1) | PE20011374A1 (en) |
| PL (1) | PL360508A1 (en) |
| SK (1) | SK17592002A3 (en) |
| WO (1) | WO2001095911A1 (en) |
| ZA (1) | ZA200209808B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001034158A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| WO2001034159A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| PL366232A1 (en) * | 2000-11-22 | 2005-01-24 | Smithkline Beecham Corporation | Protease inhibitors |
| US7709510B2 (en) | 2001-02-20 | 2010-05-04 | Chugai Seiyaku Kabushiki Kaisha | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators |
| PL204456B1 (en) | 2001-02-20 | 2010-01-29 | Chugai Pharmaceutical Co Ltd | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| AU2002342682A1 (en) * | 2001-05-17 | 2002-11-25 | Smithkline Beecham Corporation | Protease inhibitors |
| ES2309563T3 (en) | 2003-08-01 | 2008-12-16 | Chugai Seiyaku Kabushiki Kaisha | PIPERIDINE COMPOUNDS USED AS INHIBITORS FROM MALONIL COENZIMA TO DESCARBOXYLASE. |
| JP4727578B2 (en) | 2003-08-01 | 2011-07-20 | 中外製薬株式会社 | Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors |
| ES2378418T3 (en) | 2003-08-01 | 2012-04-12 | Chugai Seiyaku Kabushiki Kaisha | Cyanoguanidine-based azol compounds useful as malonyl-coadescarboxylase inhibitors |
| EP2240491B1 (en) | 2008-01-09 | 2015-07-15 | Amura Therapeutics Limited | TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES |
| CN103275070A (en) * | 2013-05-10 | 2013-09-04 | 郑彪 | Tetracyclic compound for adjusting proliferation of mononuclear cells and application of tetracyclic compound |
| US9427441B2 (en) | 2014-02-19 | 2016-08-30 | Indiana University Research And Technology Corporation | Targeting primary cilia to treat glaucoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2285A1 (en) * | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Cysteine protease inhibitors. |
| BR9916488A (en) * | 1998-12-23 | 2001-10-09 | Smithkline Beecham Corp | Protease inhibitors |
| WO2001034565A2 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| WO2001034158A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| JP2004509083A (en) * | 2000-09-01 | 2004-03-25 | スミスクライン・ビーチャム・コーポレイション | Method of treatment |
| PL366232A1 (en) * | 2000-11-22 | 2005-01-24 | Smithkline Beecham Corporation | Protease inhibitors |
| AU2002342682A1 (en) * | 2001-05-17 | 2002-11-25 | Smithkline Beecham Corporation | Protease inhibitors |
-
2001
- 2001-06-14 MX MXPA02012442A patent/MXPA02012442A/en unknown
- 2001-06-14 JP JP2002510089A patent/JP2004503502A/en active Pending
- 2001-06-14 OA OA1200200377A patent/OA12288A/en unknown
- 2001-06-14 SK SK1759-2002A patent/SK17592002A3/en not_active Application Discontinuation
- 2001-06-14 CZ CZ20024086A patent/CZ20024086A3/en unknown
- 2001-06-14 EP EP01946344A patent/EP1307204A4/en not_active Withdrawn
- 2001-06-14 IL IL15342101A patent/IL153421A0/en unknown
- 2001-06-14 NZ NZ522965A patent/NZ522965A/en unknown
- 2001-06-14 AR ARP010102840A patent/AR032622A1/en not_active Application Discontinuation
- 2001-06-14 PL PL36050801A patent/PL360508A1/en not_active Application Discontinuation
- 2001-06-14 WO PCT/US2001/019062 patent/WO2001095911A1/en active IP Right Grant
- 2001-06-14 HU HU0301231A patent/HUP0301231A2/en unknown
- 2001-06-14 BR BR0111693-2A patent/BR0111693A/en not_active IP Right Cessation
- 2001-06-14 CN CN01813500A patent/CN1444481A/en active Pending
- 2001-06-14 CA CA002412353A patent/CA2412353A1/en not_active Abandoned
- 2001-06-14 KR KR1020027017045A patent/KR20030008220A/en not_active Application Discontinuation
- 2001-06-14 EA EA200300018A patent/EA200300018A1/en unknown
- 2001-06-14 AP APAP/P/2002/002671A patent/AP2002002671A0/en unknown
- 2001-06-14 AU AU2001268407A patent/AU2001268407A1/en not_active Abandoned
- 2001-06-14 PE PE2001000566A patent/PE20011374A1/en not_active Application Discontinuation
-
2002
- 2002-11-28 BG BG107327A patent/BG107327A/en unknown
- 2002-12-02 NO NO20025786A patent/NO20025786L/en not_active Application Discontinuation
- 2002-12-03 ZA ZA200209808A patent/ZA200209808B/en unknown
- 2002-12-12 EC EC2002004388A patent/ECSP024388A/en unknown
- 2002-12-13 MA MA26952A patent/MA25758A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20025786L (en) | 2003-02-12 |
| OA12288A (en) | 2003-12-12 |
| ZA200209808B (en) | 2004-07-09 |
| EA200300018A1 (en) | 2003-06-26 |
| JP2004503502A (en) | 2004-02-05 |
| AR032622A1 (en) | 2003-11-19 |
| MA25758A1 (en) | 2003-04-01 |
| NO20025786D0 (en) | 2002-12-02 |
| EP1307204A4 (en) | 2004-06-02 |
| PL360508A1 (en) | 2004-09-06 |
| PE20011374A1 (en) | 2002-04-07 |
| WO2001095911A1 (en) | 2001-12-20 |
| NZ522965A (en) | 2004-06-25 |
| HUP0301231A2 (en) | 2003-08-28 |
| AU2001268407A1 (en) | 2001-12-24 |
| CZ20024086A3 (en) | 2003-05-14 |
| BG107327A (en) | 2003-07-31 |
| IL153421A0 (en) | 2003-07-06 |
| AP2002002671A0 (en) | 2002-12-31 |
| KR20030008220A (en) | 2003-01-24 |
| BR0111693A (en) | 2004-04-06 |
| EP1307204A1 (en) | 2003-05-07 |
| SK17592002A3 (en) | 2003-05-02 |
| MXPA02012442A (en) | 2003-04-25 |
| CA2412353A1 (en) | 2001-12-20 |
| CN1444481A (en) | 2003-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP024388A (en) | PROTEASE INHIBITORS | |
| GT200400076A (en) | CANNABINOID RECEIVER LINKS AND THEIR USES | |
| NO20044207L (en) | Cathepsin as cysteine protease inhibitors | |
| MY141596A (en) | Protease inhibitors | |
| ATE409482T1 (en) | CATHEPSINCYSTEIN PROTEASE INHIBITORS | |
| DE69939752D1 (en) | 4-amino-azepan-3-one derivatives as protease inhibitors | |
| DOP2004000888A (en) | BENZAMIDA 2-HYDROXI-3-DIAMINOALCANS (BENZAMIDE 2-HYDROXY-3-DIAMINOALKANES | |
| UY28279A1 (en) | FENACILO 2 -HIDROXI - 3 - DIAMINOALCANOS | |
| BR0210644A (en) | Compound, pharmaceutical formulation, method for inhibiting a proline / alanine cleaving protease, method for treatment or prophylaxis of disorders, and use of the compound | |
| PE20070138A1 (en) | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ASPARTILE PROTEASES | |
| TR200002940T2 (en) | Treatment of diseases caused by parasites by inhibition of cysteine proteases from the papain superfamily | |
| DE60231207D1 (en) | INHIBITORS | |
| UY26026A1 (en) | PROTEASE INHIBITORS | |
| BRPI0410157A (en) | actinonine bioisostains | |
| UY26088A1 (en) | PROTEASE INHIBITORS | |
| WO2002092563A3 (en) | Protease inhibitors | |
| WO2005013909A3 (en) | Novel cathepsin k inhibitors | |
| WO2003053331A3 (en) | Protease inhibitors | |
| AR029855A1 (en) | SALT FORMS OF AN HIV PROTEASE INHIBITOR | |
| AR123132A1 (en) | CRYSTALLINE FORMS OF AN INHIBITOR OF O-GLYCOPROTEIN-2-ACETAMIDO-2-DESOXY-3-D-GLUCOPYRANOSIDASE | |
| ECSP992905A (en) | PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MALARIA | |
| PA8601101A1 (en) | BENZAMIDA 2-HYDROXI-3-DIAMINOALCANS | |
| ECSP003353A (en) | PROTEASE INHIBITORS IX | |
| ECSP982493A (en) | PROTEASE INHIBITORS III | |
| BR9909530A (en) | Treatment of parasitic diseases by inhibiting papaya superfamily cysteine proteases |